Minneapolis, MN, April 27, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) management will be attending the Heart Rhythm Society’s 37th Annual Scientific Sessions from May 4-7 in San Francisco, CA. BioSig management recently announced an agreement with Minnetronix to initiate development of their PURE EP(TM) System, which addresses the global $4 billion electrophysiology marketplace. Additionally, the company established an advanced research program with Mayo Clinic in Rochester, Minnesota. BioSig management will be available to discuss these and other material updates at the event.
The Annual Scientific Sessions will convene the finest clinicians, scientists, researchers and innovators in the field of cardiac pacing and electrophysiology. Over the course of four days, more than 900 noted heart rhythm experts will speak at more than 250 educational sessions designed to provide practical information and best practices for physicians, allied health professionals, and basic scientists. Attendees will be immersed in the global community of professionals dedicated to improving the care of patients with heart rhythm disorders.
BioSig will be hosting an event for those interested in meeting the Company’s management and Board of Directors on Thursday, May 5 from 5:30-8 pm at the Gallery Lounge of the JW Marriott at 515 Mason Street in Union Square. To attend, please contact Brian McLaughlin, VP of Corporate Finance and Investor Relations at email@example.com or call (917) 370-9817.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System.
The PURE EP System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. firstname.lastname@example.org 917-370-9817
Source:BioSig Technologies, Inc.